Article
-
Video
The Inflation Reduction Act- Explained by Incubate
12.15.2022
Incubate breaks down the Inflation Reduction Act, diving into implications and potential impacts on life science development. Keep up with...
-
Article
US Government Poised for Long-Awaited Powers on Drug Pricing
08.06.2022
Via Bloomberg: Drugmakers have long said R&D will suffer if prices regulated
-
Article
HEALTH CARE BRIEFING: Senate Drug Measures Cut Deficit, CBO Says
08.04.2022
Via Bloomberg Government: Senate Democrats’ tax, climate, and drug-pricing bill would cut down federal budget deficits by $102 billion over 10 years, the nonpartisan Congressional Budget Office said.
-
Article
Biotech Investors Sound the Alarm on Senate Drug Pricing Bill
08.03.2022
Via the Washington Times: A group of biotech investors and doctors are warning that the Senate’s drug-pricing proposal, aimed at lowering skyrocketing prices, would “strike a huge blow” to patient access and halt research on new treatments for Alzheimer’s disease, heart disease and cancer.
-
Article
Don’t Look Up? Congress Can’t Ignore Risk to Small Molecule Drugs in Pricing Bill, Investors Warn
08.03.2022
A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.
-
Article
LTE: Patents protect people’s access to life-saving medicine
06.05.2022
See Incubate's letter to the editor about why patents are necessary in protecting patient access.
-
Article
To Spend Less on Healthcare, Invest in More Medicines
04.05.2022
Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.
-
Article
CMS’s Devastating Blow to Seniors
02.09.2022
Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.
-
Article
Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
12.02.2021
A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.
-
Article
House passage of Build Back Better gets mixed reaction
11.22.2021
As investors in biotechnology and pharmaceuticals, we're alarmed by the potential consequences of the drug-pricing measure included in the Build Back Better Act, which just passed the House.
-
Article
Regeneron, Janssen Drugs Fit Profile Targeted in Spending Bill
11.10.2021
Plan would negotiate prices of expensive older pharmaceuticals Moderate Democrats sought compromise to preserve innovation
-
Article
Drug pricing bill’s unintended consequences will distort drug development
11.09.2021
The ultimate victims of all the unintended consequences of the current proposal will be all of us as future patients.